PHR1296
Bifonazole
Pharmaceutical Secondary Standard; Certified Reference Material
Synonym(s):
1-(p,α-Diphenylbenzyl)imidazole
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C22H18N2
CAS Number:
Molecular Weight:
310.39
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
Recommended Products
grade
certified reference material
pharmaceutical secondary standard
Quality Level
agency
traceable to Ph. Eur. B1110000
API family
bifonazole
CofA
current certificate can be downloaded
technique(s)
HPLC: suitable
gas chromatography (GC): suitable
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
c1ccc(cc1)C(c2ccc(cc2)-c3ccccc3)n4ccnc4
InChI
1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H
InChI key
OCAPBUJLXMYKEJ-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
Related Categories
General description
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Bifonazole is a substituted imidazole analog with therapeutic potential in treating invasive mucosal infections. It exhibits antifungal activity by suppressing the proliferation of dermatophytes, yeasts and fungi affecting the skin and nails. Its mode of action involves blocking the fungal ergosterol biosynthetic pathway and additional inhibition of terpenoid biosynthesis.
Bifonazole is a substituted imidazole analog with therapeutic potential in treating invasive mucosal infections. It exhibits antifungal activity by suppressing the proliferation of dermatophytes, yeasts and fungi affecting the skin and nails. Its mode of action involves blocking the fungal ergosterol biosynthetic pathway and additional inhibition of terpenoid biosynthesis.
Application
Bifonazole may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using spectrophotometric technique.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
Biochem/physiol Actions
Bifonazole is an imidazole-based anti-fungal agent with broad spectrum activity against many fungi, molds, yeast and some Gram-positive bacteria. Bifonazole inhibits ergosterol biosynthetic protein 28 and Cytochrome P450 2B4.
Analysis Note
These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.
Other Notes
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
Footnote
To see an example of a Certificate of Analysis for this material enter LRAC3256 in the slot below. This is an example certificate only and may not be the lot that you receive.
related product
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Validated spectrophotometric methods for the determination of bifonazole in pharmaceuticals by charge transfer complexation
Ismail SBN, et al.
Journal of the Association of Arab Universities for Basic and Applied Sciences, 19(1), 8-14 (2016)
Determination of bifonazole in creams containing methyl-and propyl p-hydroxybenzoate by derivative spectrophotometric method
Popovic G, et al.
Journal of Pharmaceutical and Biomedical Analysis, 33(1), 131-136 (2003)
Shinichi Watanabe et al.
Mycoses, 49(3), 236-241 (2006-05-10)
The aim of the study was to compare the efficacy and safety of luliconazole 1% cream and bifonazole 1% cream as applied in the treatment of tinea pedis (interdigital-type and plantar-type). A multi-clinic, randomised single-blind, parallel group study with 34
Nehama Linder et al.
Birth defects research. Part A, Clinical and molecular teratology, 88(3), 201-204 (2009-12-17)
Neonatal limb reduction defects may be caused by exposure to an external agent. The azole derivatives are used in the treatment of systemic and dermal mycoses. Their relative teratogenic risk is still controversial. We describe two newborns with severe limb
P Ross Wilderman et al.
The FEBS journal, 279(9), 1607-1620 (2011-11-05)
Residues located outside the active site of cytochromes P450 2B have exhibited importance in ligand binding, structural stability and drug metabolism. However, contributions of non-active-site residues to the plasticity of these enzymes are not known. Thus, a systematic investigation was
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service